Despite the introduction of new AR pathway inhibitors such as abiraterone and MDV3100, clinical responses are transitory and many patients do not respond, demonstrating the importance of ligand and AR-independent mechanisms of PCa progression. This proposal evaluates the novel hypothesis that the chromatin modifying enzyme LSD1 mediates survival of ligand and AR-independent CRPC (extending its previously identified function as a driver of ligand-mediated AR activity). Specifically, we find that i. LSD1 overexpression is ubiquitous in metastatic CRPCs, including AR+ and AR- tumors;ii. the predominant category of ligand-independent LSD1 target genes involves control of the cell cycle and proliferation;and iii. LSD1 acts in an AR-axis independent manner by promoting cMyc driven tumor growth. Our data re-shape the accepted paradigm of LSD1 as a driver of ligand-mediated PCa growth, and additionally place it as a central driver in the progression of both ligand-independent AR+ CRPC and AR null CRPC. These data strongly suggest that suppression of LSDI in the clinical setting will not only inhibit AR-pathway dependent PCa, but will inhibit the growth and potentially prevent progression to fully-androgen independent CRPC, thereby establishing the rationale for LSD1 inhibition as an important, mechanism-based therapeutic target. To fully elucidate the activity of LSD1 in driving CRPC, this project will: 1. Determine the role of c-Myc in LSD1-mediated induction of ligand-independent proliferation pathways in castration sensitive and castration resistant PCa models;2. Determine the anti-tumor efficacy of LSD1 suppression using the new LSD1 inhibitor SP-2509, alone or in combination with MDV3100, in ligand-independent AR+ and AR- preclinical CRPC models;and 3. Determine the biological effects, safety, and anti-tumor activity of the new LSD1 inhibitor SP-2509 in a phase I trial in men with metastatic CRPC. The need to target and translate key mechanisms such as the activity of LSD1, which is capable of simultaneously interdicting development of both AR-dependent and AR-independent mechanisms of progression and resistance, is an innovative approach of paramount importance and will yield novel data of immediate clinical translational relevance.

Public Health Relevance

This proposal will apply novel insights regarding the role of LSD1 in promoting ligand and AR-independent CRPC survival and lethal progression. Using in vitro cell lines, in vivo xenograft models, and tumor biopsies from men with CRPC enrolled in a phase 1 study of a novel LSD1 inhibitor, we will establish the specific mechanisms by which LSD1 acts, and lay the groundwork for phase II evaluation of LSD1 inhibitor therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097186-11A1
Application #
8555009
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2002-09-19
Project End
2018-08-31
Budget Start
2013-09-17
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$149,009
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Zhang, Ailin; Zhang, Jiawei; Plymate, Stephen et al. (2016) Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression. Horm Cancer 7:104-13
Uo, T; Dvinge, H; Sprenger, C C et al. (2016) Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Oncogene :
Faltermeier, Claire M; Drake, Justin M; Clark, Peter M et al. (2016) Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A 113:E172-81
Lam, Hung-Ming; McMullin, Ryan; Nguyen, Holly et al. (2016) Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts. Clin Cancer Res :
Saranchova, Iryna; Han, Jeffrey; Huang, Hui et al. (2016) Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep 6:30555
Qu, Xiaoyu; Jeldres, Claudio; Glaskova, Lena et al. (2016) Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence. J Mol Diagn 18:215-24
Gulati, Roman; Cheng, Heather H; Lange, Paul H et al. (2016) Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev :
Shui, Irene M; Kolb, Suzanne; Hanson, Christi et al. (2016) Trichomonas vaginalis infection and risk of advanced prostate cancer. Prostate 76:620-3
Coleman, Daniel J; Van Hook, Kathryn; King, Carly J et al. (2016) Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 7:40690-40703
Pritchard, Colin C; Mateo, Joaquin; Walsh, Michael F et al. (2016) Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 375:443-53

Showing the most recent 10 out of 323 publications